NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Fortrea Holdings Inc. (FTRE) Stock Analysis

Fortrea Holdings Inc. (FTRE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

FTRE

$24.06

+$1.28 (+5.62%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FTRE with… →

FTRE Key Statistics

As of Oct 21, 2026
Trading
Open
$22.45
Previous Close
$22.78
Day's Range
22.30–24.37
52-Week Range
8.55–24.37
Volume
2.45M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.91
Valuation
Market Cap
$2.29B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
21.27
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.34
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.85
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.91
Financials (FY)
Revenue (FY)
$2.72B+1.00%
Net Income (FY)
−$986.20M
Profit marginThe share of revenue left as profit after all costs and taxes.
−3.18%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
95.10M
1-Year Return
+131.57%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
1.59M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, FTRE closed at $24.06, +131.57% over 1 year.

Fortrea Holdings Inc. (FTRE) has a market capitalization of $2.29B.

In fiscal 2025, FTRE reported revenue of $2.72B.

FTRE Stock Return by Calendar Year

Fortrea Holdings Inc. (FTRE) return since Jun 2023: what $10,000 became

1 year
$10,000 $23,157
+131.57%
3 years
$10,000 $8,454
−15.46%
Since Jun 2023
$10,000 $7,993
−20.07%

If you had invested $10,000 in Fortrea Holdings Inc. (FTRE) at the close on June 16, 2023, the earliest close on record here, it would have been worth $7,993 at the close on October 21, 2026: −20.07% in total, −6.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+39.48%
2025−7.51%
2024−46.56%
2023 (partial year)+15.95%

As of October 21, 2026.

FTRE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.72B−$986.20M−36.2%
2024$2.70B−$328.50M−12.2%
2023$2.84B−$25.20M−0.9%
2022$2.84B$186.20M6.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.72B$503.80M−$30.60M−$986.20M−36.2%
2024$2.70B$534.20M−$111.80M−$328.50M−12.2%
2023$2.84B$590.60M$53.20M−$25.20M−0.9%
2022$2.84B$724.40M$222.80M$186.20M6.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FTRE Valuation vs Biotechnology Median

Median of 608 stocks
MetricFTREBiotechnology medianvs median
P/S ratio0.8513.300.1x the median
Profit margin−3.18%−38.31%35.1 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Fortrea Holdings Inc. (FTRE) at $2.29B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 14,000 employees.

The 52-week range on file runs from $8.55 to $24.37. The most recent close on file for FTRE is $24.06, dated October 21, 2026. That is +$1.28 (+5.62%) against the previous close. The latest close sits 181.4% above that 52-week low.

Financial Health

In fiscal 2025, Fortrea Holdings Inc. reported revenue of $2.72B. Against the prior fiscal year total of $2.70B, that is a change of +1.00%. The same year closed with a net loss of $986.20M. The reported profit margin is −3.18%. That is 35.1 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are −0.91.

Across the 4 fiscal years on file, revenue moves from $2.84B in 2022 to $2.72B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 21.27. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.34. Measured against sales, the shares trade at 0.85 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +131.57%. Measured over 3 years, that is −5.44% a year compounded. Beta against the wider market is reported at 1.91. Annualized volatility over the trailing 3 years is 73.71%.

Growth & Income

No dividend is on file for FTRE.

The strongest complete calendar year on file is 2025 at −7.51%; the weakest is 2024 at −46.56%. 2026 is still running; the total return is +39.48% year to date.

Peer Comparison

Fortrea Holdings Inc. (FTRE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Fortrea Holdings Inc. FTRE $2.29B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Fortrea Holdings Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Fortrea Holdings Inc.

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Visit website →